Unknown

Dataset Information

0

Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.


ABSTRACT: Since its discovery 35 years ago, there have been no therapeutic interventions shown to enable full HIV-1 remission. Combined antiretroviral therapy (cART) has achieved the sustained control of HIV-1 replication, however, the life-long treatment does not eradicate long-lived latently infected reservoirs and can result in multiple side effects including the development of multidrug-resistant escape mutants. Antibody-based treatments have emerged as alternative approaches for a HIV-1 cure. Here, we will review clinical advances in coreceptor-targeting antibodies, with respect to anti-CCR5 antibodies in particular, which are currently being generated to target the early stages of infection. Among the Env-specific antibodies widely accepted as relevant in cure strategies, the potential role of those targeting CD4-induced (CD4i) epitopes of the CD4-binding site (CD4bs) in eliminating HIV-1 infected cells has gained increasing interest and will be presented. Together, with approaches targeting the HIV-1 replication cycle, we will discuss the strategies aimed at boosting and modulating specific HIV-1 immune responses, highlighting the harnessing of TLR agonists for their dual role as latency reverting agents (LRAs) and immune-modulatory compounds. The synergistic combinations of different approaches have shown promising results to ultimately enable a HIV-1 cure.

SUBMITTER: Siracusano G 

PROVIDER: S-EPMC8750418 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3824676 | biostudies-other
| S-EPMC3730421 | biostudies-other
| S-EPMC5694689 | biostudies-literature
| S-EPMC9215120 | biostudies-literature
| S-EPMC5122442 | biostudies-literature
| S-EPMC4635699 | biostudies-literature
| S-EPMC7019976 | biostudies-literature
| S-EPMC6539195 | biostudies-literature
| S-EPMC4817793 | biostudies-literature
| S-EPMC4731181 | biostudies-literature